The FDA approval of Zavzpret, which Pfizer announced in March 2023, is good news for people living with migraine, as it becomes an important option to help combat this disease.
One study published in “Neurology” last year found that Black patients are less likely than white patients to receive a headache diagnosis (47% versus 70%), and less likely to receive a prescription for migraine medication (14% versus 37%).
Migraine is a Health Disparity for People of Color Act Now to Support a Congressional Resolution on Health Equity
By Jaime M. Sanders, The Migraine Diva, Co-Lead of the Disparities in Headache Advisory Council
Published June 10, 2021
The Coalition for Headache and Migraine Patients (CHAMP) and its partners realized that meaningful change was required. They created the Disparities in Headache Advisory Council that has held numerous training sessions and provided seed-funding for new initiatives that promote diversity and equality in headache medicine.
(Photo: iStockphoto / NNPA)
Migraine is a neurological disease that affects 60 million Americans and is the 2nd leading cause of disability worldwide. It is an underestimated, underdiagnosed, and undertreated disease despite its heavy burden. However, communities of color, which have been historically, socially, and economically disenfranchised from research studies and treatment are bearing the brunt of this burden. The Americ